Mammography-Associated Pain: Contributing Factors and Mitigation Strategies
Journal of Breast Imaging · 24.07.2026
DOI: 10.1093/jbi/wbag039 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Breast Imaging, online erschienen am 24.07.2026. Verfasst von Anne-Marie LaBorde und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Ochsner Health System, New Orleans, Louisiana, USA. Die Arbeit nennt 51 Literaturangaben.
Abstract (Originalsprache)
Pain is one of the most common negative experiences with screening mammography, and it is an unavoidable limitation due to the necessity of breast compression. Unfortunately, mammography-associated pain discourages many women from screening attendance. This article reviews the multifactorial etiologies of mammographic pain: technical, physiologic, psychological, and demographic variables. Because mammography remains the only screening modality proven to reduce breast cancer mortality, it is imperative that radiologists understand the factors contributing to mammography-associated pain and implement evidence-based strategies to mitigate this screening barrier. These strategies include pharmaceutical, physical, technologic, and psychological solutions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, Ochsner Health System, New Orleans, Louisiana, USA.
ORCID-Profile: Vilert A Loving
Zitieren
APA
LaBorde, A. M., Sun, L., & Loving, V. A. (2026). Mammography-Associated Pain: Contributing Factors and Mitigation Strategies. Journal of Breast Imaging. https://doi.org/10.1093/jbi/wbag039
Vancouver
LaBorde AM, Sun L, Loving VA. Mammography-Associated Pain: Contributing Factors and Mitigation Strategies. Journal of Breast Imaging. 2026. doi:10.1093/jbi/wbag039
BibTeX
@article{LaBorde2026,
author = {LaBorde, Anne-Marie and Sun, Lu and Loving, Vilert A},
title = {Mammography-Associated Pain: Contributing Factors and Mitigation Strategies},
journal = {Journal of Breast Imaging},
year = {2026},
doi = {10.1093/jbi/wbag039}
}
EUVIMED